0001193125-19-273579.txt : 20191024 0001193125-19-273579.hdr.sgml : 20191024 20191024160555 ACCESSION NUMBER: 0001193125-19-273579 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20191024 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191024 DATE AS OF CHANGE: 20191024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RESMED INC CENTRAL INDEX KEY: 0000943819 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980152841 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15317 FILM NUMBER: 191166499 BUSINESS ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 BUSINESS PHONE: 8587462400 MAIL ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 8-K 1 d806534d8k.htm 8-K 8-K
RESMED INC false 0000943819 0000943819 2019-10-24 2019-10-24

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Under Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 24, 2019

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

  

001-15317

  

98-0152841

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

9001 Spectrum Center Blvd.

San Diego, California 92123

(Address of Principal Executive Offices)

(858) 836-5000

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.004 par value

  

RMD

  

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act  ☐

 

 

Item 2.02. Disclosure of Results of Operations and Financial Condition.

On October 24, 2019 we issued the press release attached as Exhibit 99.1. It is incorporated into this report by reference. The press release describes the results of our operations for the quarter ended September 30, 2019.

Item 8.01. Other Events.

On October 24, 2019 we announced that our board of directors declared a quarterly cash dividend of US $0.39 per share. The dividend will have a record date of November 7, 2019, payable on December 12, 2019. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 6, 2019 for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 6, 2019 through November 7, 2019, inclusive. 

Item 9.01. Financial Statements and Exhibits.

  (d) Exhibits

Exhibits:

   

Description of Document

         
 

99.1

   

Press Release dated October 24, 2019 regarding results of operations

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: October 24, 2019

 

 

RESMED INC.

 

 

(registrant)

             

 

 

By:

 

/s/ Brett Sandercock

 

 

Name:

 

Brett Sandercock

 

 

Its:

 

Chief Financial Officer

-3-

EX-99.1 2 d806534dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO  

 

For investors   For media
Amy Wakeham   Jayme Rubenstein
+1 858-836-5000   +1 858-836-6798
investorrelations@resmed.com   news@resmed.com

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2020

 

  •  

Year-over-year revenue grows 16%, non-GAAP operating profit up 22%

 

  •  

Balanced growth across product portfolio and global markets

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, October 24, 2019 – ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading connected health company, today announced results for its quarter ended September 30, 2019.

First Quarter 2020 Highlights

 

  •  

Revenue increased 16% to $681.1 million; up 17% on a constant currency basis

 

  •  

Gross margin expanded 120 bps to 59.5%

 

  •  

Net operating profit increased 19%; non-GAAP operating profit up 22%

 

  •  

GAAP diluted earnings per share of $0.83; non-GAAP diluted earnings per share of $0.93

“Our global ResMed team delivered another quarter of strong performance in the first quarter of fiscal year 2020 with double-digit topline revenue growth, balanced growth across our businesses and regions, and further improvements in operating leverage resulting in double-digit growth at the bottom line,” said Mick Farrell, ResMed’s CEO. “We were particularly pleased that strong customer demand for our new products drove high-teens growth in the mask category during the quarter. Through organic growth and targeted acquisitions, we’re driving forward every facet of our business, leading the innovation of devices and software that improve health outcomes, create efficiencies, and reduce overall healthcare system costs. We’re well on our way to improving 250 million lives in out-of-hospital healthcare in 2025.”

RMD First Quarter 2020 Earnings Press Release – October 24, 2019    Page  2  of 9

 

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

 

     Three Months Ended  
     September 30,
2019		     September 30,
2018		     % Change     Constant
Currency (A)		  

Revenue

    $ 681.1     $ 588.3       16 %      17 % 

Gross margin

      59.5 %      58.3 %      2    

Selling, general and administrative expenses

      167.4       147.3       14       16  

Research and development expenses

      48.0       38.8       24       27  

Income from operations

      171.1       144.1       19    

Non-GAAP income from operations (B)

      191.0       157.0       22    

Net income

      120.1       105.7       14    

Non-GAAP net income (B)

      135.4       116.3       16    

Diluted earnings per share

    $ 0.83     $ 0.73       14    

Non-GAAP diluted earnings per share (B)

    $ 0.93     $ 0.81       15    

 

(A)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Discussion of First Quarter Results

 

  •  

Revenue in the U.S., Canada, and Latin America, excluding Software as a Service, grew by 13 percent compared to the prior year period, driven by strong sales across our mask and device product portfolios.

 

  •  

Revenue in combined Europe, Asia and other markets grew by 8 percent on a constant currency basis compared to the same period of the prior year. Mask sales were strong across these markets. As expected, device sales in France and Japan were impacted as customers manage their fleets following the completion of their connected device upgrade programs. Device sales outside France and Japan grew well.

 

  •  

Software as a Service revenue increased by 83 percent, compared to the prior year period, due to continued growth in Brightree service offerings and incremental contribution from the acquisition of MatrixCare, which closed in the second quarter of fiscal year 2019.

 

  •  

Gross margin expanded by 120 basis points over the prior year period, primarily due to benefits from manufacturing and procurement efficiencies, and higher margin contribution from MatrixCare.

 

  •  

Selling, general, and administrative expenses increased by 14 percent compared to the prior year period, or by 16 percent on a constant currency basis. Excluding the impact of recent acquisitions, selling, general, and administrative expenses increased by 6 percent on a constant currency basis. SG&A expenses improved to 24.6 percent of revenue in the quarter, compared with 25.0 percent in the same period of the prior year.

 

  •  

Income from operations increased by 19 percent and non-GAAP income from operations increased by 22 percent compared to the prior year period.

 

  •  

Net income and diluted earnings per share both grew by 14 percent, predominantly attributable to strong sales, particularly in masks, coupled with controlled operating costs compared to the prior year quarter.

 

  •  

Non-GAAP net income grew by 16 percent and non-GAAP diluted earnings per share grew by 15 percent compared with the prior year quarter.

 

  •  

Cash flow from operations for the quarter was $162.4 million, compared to net income in the current quarter of $120.1 million. During the quarter we paid $56.1 million in dividends.

 

RMD First Quarter 2020 Earnings Press Release – October 24, 2019    Page  3  of 9

 

Other Business and Operational Highlights

 

  •  

The Lancet Respiratory Medicine published a multinational analysis by ResMed and 12 academic leaders in sleep research indicating more than 936 million people have obstructive sleep apnea.

 

  •  

Completed a $500M private placement debt offering, significantly lengthening average debt maturity profile and providing improved visibility into long-term funding costs. Net proceeds were used to pay down current borrowings on ResMed’s senior unsecured revolving credit facility.

 

  •  

Named Dealmaker of the Year by Medtech Insight, an award that recognizes the company most adept at advancing its business through investment deals. During the entry period (June 2018–June 2019), ResMed announced the acquisition of five companies to advance its mission to help keep millions of people healthy and out of the hospital.

 

  •  

Celebrated 20 years listed on the New York Stock Exchange (NYSE) and 30 years in business by ringing the Opening Bell ® at the NYSE on its listing anniversary.

Dividend program

The ResMed board of directors today declared a quarterly cash dividend of $0.39 per share. The dividend will have a record date of November 7, 2019, payable on December 12, 2019. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 6, 2019, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 6, 2019, through November 7, 2019, inclusive.     

Webcast details

ResMed will discuss its first quarter fiscal year 2020 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q1 2020 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on our website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 800-585-8367 (U.S.) or +1 416-621-4642 (outside U.S.) and entering the passcode 1076268. The telephone replay will be available until November 7, 2019.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.

 

RMD First Quarter 2020 Earnings Press Release – October 24, 2019    Page  4  of 9

 

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

 

– More –

RMD First Quarter 2020 Earnings Press Release – October 24, 2019    Page  5  of 9

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Income

(Unaudited; $ in thousands, except for per share amounts)

 

     Three Months Ended  
     September 30,
2019		     September 30,
2018		  

Net revenue

    $ 681,056     $ 588,279  

Cost of sales

      276,001       245,186  
  

 

 

    

 

 

  

Gross profit

    $ 405,055     $ 343,093  

Operating expenses:

     

Selling, general and administrative

      167,440       147,303  

Research and development

      48,033       38,791  

Amortization of acquired intangible assets (1)

      18,480       12,867  
  

 

 

    

 

 

  

Total operating expenses

    $ 233,953     $ 198,961  

Income from operations (1)

      171,102       144,132  

Other income (expenses), net:

     

Interest income (expense), net

    $ (10,543 )    $ (2,786 ) 

Loss attributable to equity method investments

      (6,863 )      —    

Other, net

      (3,109 )      (2,465 ) 
  

 

 

    

 

 

  

Total other income (expenses), net

      (20,515 )      (5,251 ) 
  

 

 

    

 

 

  

Income before income taxes

    $ 150,587     $ 138,881  

Income taxes

      30,439       33,144  
  

 

 

    

 

 

  

Net income

    $ 120,148     $ 105,737  
  

 

 

    

 

 

  

Basic earnings per share

    $ 0.84     $ 0.74  

Diluted earnings per share

    $ 0.83     $ 0.73  

Non-GAAP diluted earnings per share (1)

    $ 0.93     $ 0.81  

Basic shares outstanding

      143,719       142,668  

Diluted shares outstanding

      145,099       144,030  

 

(1)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

 

– More –

RMD First Quarter 2020 Earnings Press Release – October 24, 2019    Page  6  of 9

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands)

 

     September 30,
2019		     June 30,
2019		  

ASSETS

     

Current assets:

     

Cash and cash equivalents

    $ 172,154     $ 147,128  

Accounts receivable, net

      493,836       528,484  

Inventories

      357,033       349,641  

Prepayments and other current assets

      138,075       120,113  
  

 

 

    

 

 

  

Total current assets

    $ 1,161,098     $ 1,145,366  

Non-current assets:

     

Property, plant and equipment, net

    $ 382,970     $ 387,460  

Operating lease right-of-use assets

      81,650       —    

Goodwill and other intangibles, net

      2,353,274       2,378,399  

Deferred income taxes and other non-current assets

      175,566       196,457  
  

 

 

    

 

 

  

Total non-current assets

    $ 2,993,460     $ 2,962,316  
  

 

 

    

 

 

  

Total assets

    $ 4,154,558     $ 4,107,682  
  

 

 

    

 

 

  

LIABILITIES AND STOCKHOLDERS’ EQUITY:

     

Current liabilities:

     

Accounts payable

    $ 109,742     $ 115,725  

Accrued expenses

      231,253       266,359  

Operating lease liabilities, current

      19,548       —    

Deferred revenue

      86,954       88,667  

Income taxes payable

      90,968       73,248  

Short-term debt

      11,992       11,992  
  

 

 

    

 

 

  

Total current liabilities

    $ 550,457     $ 555,991  

Non-current liabilities:

     

Deferred revenue

    $ 82,668     $ 81,143  

Deferred income taxes

      15,177       11,380  

Operating lease liabilities, non current

      65,838       —    

Other long term liabilities

      2,047       2,058  

Long-term debt

      1,208,210       1,258,861  

Long-term income taxes payable

      112,910       126,056  
  

 

 

    

 

 

  

Total non-current liabilities

    $ 1,486,850     $ 1,479,498  
  

 

 

    

 

 

  

Total liabilities

    $ 2,037,307     $ 2,035,489  
  

 

 

    

 

 

  

STOCKHOLDERS’ EQUITY:

     

Common stock

    $ 575     $ 575  

Additional paid-in capital

      1,530,011       1,511,473  

Retained earnings

      2,500,506       2,436,410  

Treasury stock

      (1,623,256 )      (1,623,256 ) 

Accumulated other comprehensive income

      (290,585 )      (253,009 ) 
  

 

 

    

 

 

  

Total stockholders’ equity

    $ 2,117,251     $ 2,072,193  
  

 

 

    

 

 

  

Total liabilities and stockholders’ equity

    $ 4,154,558     $ 4,107,682  
  

 

 

    

 

 

  

 

– More –

RMD First Quarter 2020 Earnings Press Release – October 24, 2019    Page  7  of 9

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in thousands)

 

     Three Months Ended  
     September 30,
2019		     September 30,
2018		  

Cash flows from operating activities:

     

Net income

    $ 120,148     $ 105,737  

Adjustment to reconcile net income to cash provided by operating activities:

     

Depreciation and amortization

      37,954       30,424  

Amortization of right-of-use-assets

      5,963       —    

Stock-based compensation costs

      13,256       12,477  

Loss attributable to equity method investments

      6,863       —    

Impairment of equity investments

      2,590       1,711  

Changes in fair value of business combination contingent consideration

      (8 )      (183 ) 

Changes in operating assets and liabilities, net of effect of acquisitions:

     

Accounts receivable, net

      28,286       20,342  

Inventories, net

      (14,204 )      (15,661 ) 

Prepaid expenses, net deferred income taxes and other current assets

      (8,407 )      (7,703 ) 

Accounts payable, accrued expenses and other

      (30,078 )      (99,025 ) 
  

 

 

    

 

 

  

Net cash provided by operating activities

    $ 162,363     $ 48,119  

Cash flows from investing activities:

     

Purchases of property, plant and equipment

      (22,671 )      (12,994 ) 

Patent registration costs

      (2,069 )      (2,611 ) 

Business acquisitions, net of cash acquired

      —         (126,439 ) 

Purchases of investments

      (2,741 )      (2,467 ) 

Proceeds / (Payments) on maturity of foreign currency contracts

      (5,743 )      (3,678 ) 
  

 

 

    

 

 

  

Net cash used in investing activities

    $ (33,224 )    $ (148,189 ) 

Cash flows from financing activities:

     

Proceeds from issuance of common stock, net

      5,609       513  

Taxes paid related to net share settlement of equity awards

      (326 )      (124 ) 

Purchases of treasury stock

      —         (19,399 ) 

Payment of business combination contingent consideration

      (302 )      (240 ) 

Proceeds from borrowings, net of borrowing costs

      565,000       303,000  

Repayment of borrowings

      (614,003 )      (86,133 ) 

Dividends paid

      (56,052 )      (52,793 ) 
  

 

 

    

 

 

  

Net cash (used in) / provided by financing activities

    $ (100,074 )    $ 144,824  
  

 

 

    

 

 

  

Effect of exchange rate changes on cash

    $ (4,039 )    $ (3,267 ) 
  

 

 

    

 

 

  

Net increase / (decrease) in cash and cash equivalents

      25,026       41,487  

Cash and cash equivalents at beginning of period

      147,128       188,701  
  

 

 

    

 

 

  

Cash and cash equivalents at end of period

    $ 172,154     $ 230,188  
  

 

 

    

 

 

  

 

 

– More –

RMD First Quarter 2020 Earnings Press Release – October 24, 2019    Page  8  of 9

 

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measure, “non-GAAP income from operations” is reconciled with GAAP income from operations below:

 

     Three Months Ended  
     September 30,
2019		      September 30,
2018		  

GAAP income from operations

    $ 171,102      $ 144,132  

Amortization of acquired intangible assets (A)

      18,480        12,867  

Deferred revenue fair value adjustment (A)

      1,445        —    
  

 

 

     

 

 

  

Non-GAAP income from operations

    $ 191,027      $ 156,999  
  

 

 

     

 

 

  

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

     Three Months Ended  
     September 30,
2019		      September 30,
2018		  

GAAP net income

    $ 120,148      $ 105,737  

Amortization of acquired intangible assets, net of tax (A)

      14,122        9,987  

Deferred revenue fair value adjustment, net of tax (A)

      1,107        —    

U.S. tax reform

      —          534  
  

 

 

     

 

 

  

Non-GAAP net income (A)

    $ 135,377      $ 116,258  
  

 

 

     

 

 

  

Diluted shares outstanding

      145,099        144,030  

GAAP diluted earnings per share

    $ 0.83      $ 0.73  

Non-GAAP diluted earnings per share (A)

    $ 0.93      $ 0.81  

 

(A)

ResMed adjusts for the impact of the amortization of acquired intangibles and deferred revenue fair value adjustment, from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

 

– More –

RMD First Quarter 2020 Earnings Press Release – October 24, 2019    Page  9  of 9

 

RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region

(Unaudited; $ in thousands, except for per share amounts)

 

     Three Months Ended  
     September 30,
2019		      September 30,
2018		      % Change     Constant
Currency (A)		  

U.S., Canada and Latin America

           

Devices

    $ 186.9      $ 172.4        8 %   

Masks and other

      183.4        154.0        19    
  

 

 

     

 

 

     

 

 

    

Total Sleep and Respiratory Care

    $ 370.3      $ 326.4        13    

Software as a Service

      86.9        47.5        83    
  

 

 

     

 

 

     

 

 

    

Total

    $ 457.2      $ 373.9        22    
  

 

 

     

 

 

     

 

 

    

Combined Europe, Asia and other markets

           

Devices

    $ 151.9      $ 151.7        0 %      4 % 

Masks and other

      72.0        62.7        15       19  
  

 

 

     

 

 

     

 

 

    

 

 

  

Total Sleep and Respiratory Care

    $ 223.9      $ 214.4        4       8  

Global revenue

           

Devices

    $ 338.8      $ 324.1        5 %      6 % 

Masks and other

      255.4        216.7        18       19  
  

 

 

     

 

 

     

 

 

    

 

 

  

Total Sleep and Respiratory Care

    $ 594.2      $ 540.8        10       11  

Software as a Service

      86.9        47.5        83       83  
  

 

 

     

 

 

     

 

 

    

 

 

  

Total

    $ 681.1      $ 588.3        16       17  
  

 

 

     

 

 

     

 

 

    

 

 

  

 

(A)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

 

– End –

EX-101.SCH 3 rmd-20191024.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rmd-20191024_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rmd-20191024_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g806534g1024165352596.jpg GRAPHIC begin 644 g806534g1024165352596.jpg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end EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-273579-xbrl.zip M4$L#!!0 ( +J 6$^:E*4/_ \ $-T . 9#@P-C4S-&0X:RYH=&WM M'6MSXCCR^U7=?U QMWM)56QL(!D@"5=9PNQRNTFF(%.[=U^VA"V":HSMDT2 M^_77+3\P8 B$O(]438)12^IN=;?Z(7G._C$9>N2>"R9P;BKIBTY'3R ]\?#=,NX_'8U%-A-U>)(O8K M I !4$QP)^DW\;C_?:[;N*P[V;5:K:A;$] ER'2"DF65B]C7C V';QCZO?NLZ #:G!?:FH[Z2SC)18 MB5.M"*T)()=!I61_7D- #)%VF*R"M0'6!W+9'S]U?IN!JWSX&6A1">K+?B"& M5('XX$C'AE4R2B>900P0CKF!$F%Y:)QJ1AHD=_(E#AH0W)X7'@3AZSBSP'1L M=1=D.@8^*4:-,>AJR4+]*&A%8=3%OXHKCS6JQJ]GQ>@C?#=DBA(A1Z>H-:S0(&=\4L<>3,2?N>LR/_H,(->1RA . OV+;OH3-/?/E@]X3COL MCDM<$'5-AX"3#[]A L;K^>T:YXGJL#Y C81>P3^U/MN64:K\J8+,4Z'1:76O M6I>D?=T\*\YALX3=;.*+(?-=^*>^>/1NZQG[U)/LHT376I+0C,1;19JZ-)/"]( M/@P]E&S]W4 @*F"ZC,0\F1/I)JU4.") ^=G8"#Z#>6V<%>?)B8F?(U@_RV D MHD>MX/68VWKQ-N!VTHWIM4L?N8M?]#D31*/ -8^Y?SJDXH[[=8O0D0H*\]UP,H-Z_,ZO.\ ")K ] M3%K1UAL#QN\&JFZ9QS!N+Q" @=$+E J&^)T53H@,/.Z23Y;^B:>V+>N'>&9# M!6$=D8H?D\ZA*C1^_&2?6*=GQ;"10]/FR)6?%K52/FKIU(N$3++#5; S=LMT MT*O3IT/N3>NW?,@DN69CT@F&U#_5;>.(CE[@N:=+9)]F%K>:Q\<%:@J-;JOY MK=.^;;>ZY.+ZDK3^:/YR*ROZBCK"R)AKY"'$CC0QZE$"#V<[IY!.I>L MR5HA>=XUGRQB5VA\N>EM0#T[ MK>M;TFE]O>G#2Z10P8GZA<>.HH <+7JH< M$>RWU^Q-Q*%4V4P MWC,)>*Y/MJ2%!ZT)!6U#]"(Q3Q F5))NR!STI%W"?=(<@"?,Q.$'$"!,!="> MQXC#/ ^6P=&I-:N@GT/JNLESA)O^N.2)5V=>J1-X'@TEJTL64M!@EC3$8]?S MG-/58K;,HR6R"Q$1(OKC)MA%LY0K/YRBDZK0&TO ZWVRO;D=,WJ"T>^848.HK$[O ^XNBFAA8>A[)A1WJ!=+%/#D-%X1X&+A-55E MI6&/=!V4.A"P"V@#WE4@!C0S&H8J%(KC':='.7S*/CL'D MY]GWG!7+8>M,,3:!?A^+\(5[#-I@ WQ$YLZB"]GF7.BC0=,\X7K"B9E_.V[3?B M*SAI7%@'OSJ 4YJ!Y7#S<7A=\" MV!:^#@+_L1YRM7QB'$-(_L9D8):S^/%3M61_/I5$,8^%2"GQ-:E'!&3#&^$N M2"!FHD"YRSY")F,SKF?H0FP?(<#- 7.^ZWPM#<$DA8*C']L+)J3'O&!,>)3, M_0(FC%2-7TF?>\AK+H'QBODNHSX*1]*9$@L#)_E3WC#L$/< R MVI+C_+"89:1&.I--_6G2U@\\F!S[H9GDZ,W)^H(TKB7N)*WF[9H26L'YQ011 M\F%I23+YH2VWQGB.R+O;*'A:#)>BN2L_G.;XCN,!5TSGL1BH_%C0\'0Q"[JI MOONXOWEKC.'O@BL0%G3-1W[LF$'@]"H*B0%Q1A6J?*Y7391NFT[$_ M?BJ7\KSJ)]2NI?4K-&+"@=(LY20<"3E"P0?5Z8Q -BNEXU@)%BHG6# YL#^3 MYI<.*94M$P /U[JR>ZUX-UK1A3W$@67V[Z[ YH+A]?X?5&)&-1G&9"_K@UVA MAEW*J,1H>;:4H$N]>5CZDK;2E'3.PUY@&-*3.C=[X M+.,+1@$3$Q!R9%XQ:S&KH!:S"LNV9,'B M1%U?-?E_B]EUTV;=Z1!&.I ; M5IT^XCHDAYZT3++8O+]R&=8GH,^ SLR*[U8>_RAG;.(-;FJ7>MJ6;)V\1A\( MN-M5@?/]B/S-,BVK0F!O(O?4&^U/T<1LCDU39!RVOTEV=;EGY+R\)E[C8V[F M+7G::*.28N#UO[JM]2=I7MP);?LN>M2,]*;$T04# /D.!HWIPRX+V7PN"40[ MX([C*'?D3@1C-4#'/,0,/Y7$97WN1V=/H^RG=4R6#XW/SHJ7R0%*T.=3G0%- M@&$:6($03Z[BN9O(NR_UC%+.6'D'T--!T=.?]U2XJ"XYZH$(C TY@V\6=-X'\>\:_[#&01O OO3&=RK]']Q;P:GWJBT+('XCZ MIYK^.4VIG&1(B*[.ZUD>>;OUF1**2Z[!.\HPVM;F*<:V8L-(2$JF53+)EHFX M=1[4(S-SEUPZ7B!'(KY^(D>>TL=Y;L &QMDYL&3D2VKDF@$876PP(^RCL.@% MG1V=WK[Q27S3*N9G?-V*C!EX-G*$]AQ,:JA/)PDP_13,/54*0DUHHNAK#'B/ M*U*KF;9)VBHZ*Y&K[X $Y6ONHTI+?"\ -0C5PN0"O)Q 863@>Q00Y393 M _^-R@' H*_D:_AO74P3E&OHC1$Y@ Z1UJ4P8^YYX-G=P[2@;J"Z+G'CZZ'7 MP7U&F3Y'"!Z1D$ZU3H#G=88>*#KE.@[ZA@>H(5Q!&S!%/VX M:\N$C&WG%7/3(W!.E.^0F.] UU*??8,O4/-Q,?X5@*.JLR&IWV>27V;#-0=H M6R[!](!/2L64M'V)9X1Q^1?'NQBAF^MQ\!+SHBE-!3"(X9%,=*?Q13O4PSH, M':+#BJ1EQD@(/"+X-A(WF27)T!&AF>S'9B[E^Y'>*,!$HI^-V&&[;=5MHBT? M\%&-(70FS+).LTO^TDLE[$; MGRY'LFB( [8!0LE"FO$RZH A9AF*Z9C"!T'Z(AA&'._^D:ZT9$IY45DKMO) MNX X5Q[%R42-'L97XV1X$!T7]Q*,#AQ8:.P"05S\UC&9\HJK!4E"G!'?)#\I M(YSR"5<#$8SN!JNT09_)E$"8.7-<]SO-Z^TTM3>RT\Q\/7VD/C(Y*'BQS_3@ M]K,_G;#YZ81%I-:D8=>=:"@T#MS#;65G=U%))")7()ZDJ&W/V/WZ5>U5)>S5 M%>F3M?7J6J:^)YH518O8FNJ ,NY^)?KS*X=)!_L929O-LO>E^B MT?-@9YS)8CT.F7*8OBDWEDB*I366C$U>L)*+Y!9%EH<+OH]9V]C$/,'*+AB, M9US72QU7A\FEA.0U+ME5SM&=C 7)J<#&Z;$J&(4U''Y#4$]7?'Y8;.;K>P\* MR%8;Q@[2/(_6@BAN)]/;E!@Q0;2#1?.S-QTN8#]NJ[*W'RUB/9H YFJ\@UZ2-;B=U]"7D2ZHH MT>]Y., LB(O9=JSE\BB#U=;.!L&W;A,W]BT.EZW#+,S=L*:75-D>D9=][&D8 MHV20M%Z;XIB\'U-^ M^I""X>3YY@?<%R&WFJ6R8[[@&8^C M[IA,BE[U65_AT:W:05]C-]N9T!V)2=,\Y<+3$O;4J>3L?VU@/N!OOV_1W8OG M"XCGSH0=S X$YCAXVX=_]LE&T=C'!-OK\ ?6X;=%S$_3U2G]MT#0/ 5H,/)) M7)4&7SAS6F@499'\))A2I$OQ_JN#E?_]_OE.Q/5#$8/W9MZV]FUO3O::]4Y7 M[D,1TUY7J7Z7%#4'G/4S)\6CMS^*=YI++6^32STKZO^#\$S_#X6-_P%02P,$ M% @ NH!83S]O$MTL, E8H" !$ !D.# V-3,T9&5X.3DQ+FAT;>U] M;5?B2K;P=]?R/]1R3L]TKQMI$A((:KNN;Z>;>;1UQ)XSYWXKDD(R'1(F+]K. MKW_VKDI"0% B2*+4K'M/(R2I73N[]OO+P;>;B_/#@V]G1Z>'VUL'-YV;\[/# MLW_MMMLU]>"S^!.^_YQ<0 Z.+T__),=?3R[/+Z^_[/SQK7-SMH,_D.TMN.Z$ M>1$+#@].._\DW9L_S\^^[-P[=C38,VN&X^T0ZCJWWI<=E_4C?M?!57K9D :W MCK<;^:.]^BC:)\G?/3^*_*'XJN][T6[H_)?MJ>._^W3HN ][-\Z0A>0[NR?7 M_I#"2D?GG:_?O^P$SNT ECHX/CS[-7!Z3D1P9^3@\_'AP>>KPQP N:=K\/0I M>!Z!LW/X5Z\7CO;Q*;#Q>?N8L8WD*P[9GOIAGT3L5[3K>#;@;D_[@'CAN.Q< M?"7=ZY,O.[=FO6DT]%NUKNDJ?#(TH]VL_7MTB[N\^;)S?OGU$N\ZP#T=XUY3 MT(YA@RO;)4'Z.#H^/R,G9^?GW:NCD\[WKU]VZCO\[ZNCT]/T[S\ZIS??ONRH M]?J''7)\>7UZ=LV_3V 0W^P""9T?777/]M(/3[[1Z=>?O6&+DYS &@?Q^C#Y M<)H"HK^8Y-B6SJ< @Y>"R?=W_V .-X="R,_" 7ICD&Y]\'%/']W 6F8>Z:C>:N4:_7#S[CU8?9/R]&SDHA:[;:Y@S(UHOK M@Q^'Z1$(F$LCQ_?"_PU8"(1++$U? MH1 M+V0>&>Y,<77CPRRZ2'YL@.C*DTCZ_J'I[UFWJU&TS%L@_:/):I*V) M7Q/TDLF70^93VJ(G[*!SB,2QZ]^Q8/#SQU^@*YR!VK&<9+TN-'T>$Q= M"MS-YA08#0BU C\,D9+LV(K(R ^BON\Z/J$>7./Z/6!PL.Q/%H5(8&0V?HS0.^JXM <$0B.B[S7J9%0;ULC9#8E\FS[@MR"4!E$TVOO\.95\M4GY1'#C M3Q@@J]EE]^@[.>V@I$A(1)X- M[&DL\ASX]S]"V&UO,;";;-)EHX@-,] :=0%:;=K\R2/'7 D)@#H](7VYN/T& MMIV+]EWXM*4I&=VF,;KK1,PZG@5H"H%T0=0"M9/?FJ9:4P70\"A@=' WR$^U M]8'X'IP<."MA1+V(6'& _.2!]&CHA OP/4EOFTMO7[D0%4\A[!.#)"))1$\0T7<6/=;M,QLO(,A93]W>RC^VW9C#*.=HF"M1O_&-M?8O MXR U>A(].V)T2&SF.F#"PY_4\Z,!H.$_8R]0& 4^'B\6@-8\1.,*#BUW&/6Y MRIJ[M"\<1@^IPVA[Z]X!==SV8[!0=FWG%LXG;,EU/#;A*8@&"J@A,PTW'R#N MQ2'<$8:P([3: G:+;CN%_]&/ PZP,X3S?\>&S -M&> ;\P47%@K@1"3*/WX% MOT_ E"X9\6T)'!.$4D&TF?LDI(Y-+ASK)_F=HN/05:;LLY.SRQH1./Z#P;8! MF60$>'&LV*6!^T!&KN!RT0!625!JQ6"-#0%XFPWY7L JP?UZ\-H2@S4D-FZ+ M#, ,V(T8\\(4V.0=#&GX$TS"B-WZP0.QXP#WAS\DKZ5&;@:!']\.B!_<4L^Q MLLW"@A$0%4-BI=9_8B=T(H'7>R:V!7NP ^<.GPB@W=, J!IP^4#Z< "XD9I_ M.\KV5FJ0X?H.&%UWW,&*%]KLSK&2]Q?Z_>@>CP/'1?+B4M/-CR.PWAA @7(A M8H3U^X[E@*;JL.25 YW&0(3H=$)36-QHX0/#AQ#L-]!QPRBLD3_&V[B'5X;Z M+\)[#Q8A:"QB7816,^H3"C/!P\"):$'G]_;6$Y? AG;]_N[ #T=.1-U)#W@> M>%@/SHQ12T@N,<@_GW;^"5,$(^.B)=Y/9?_I;C]3T&;PEXO0L[#/^& M-W^[)MW._P%@C1TA';[L\(CKWE_:_']3,;:$]YZN+QKATV9'^,R) -_ZHAJ=P^N+4S+#A7"62J$KX'[H\N=L*/6U)(X8DOI@ MA"/HN?#'TT$0\OWRC^NC*X3I"G:<7MQ!'P=\!W=H8IGT3W&%WY^^LIV[+ -L M2EZ.%HV7DSPBS>FX^^LE$ C/C@>2S1$RE[N?D(M=9@+J@D6!8X4SHRLY<)HK M\C7^\&AL Y^R]\EOR'02K@?,E?VR&* *Q=!8%:)#/_:X!ZJSPER'PARBK54C M":"I+LHBS$D6\?3GYQ[6>A\/>PVV:,[@BL_':Q=E:>EN@;" 2N$+59\FEW0G M/3^P69 2O%JK(]\)?11QD/SE0BU] M#7(M I9AFK7&FL!Z_IQ-PJ8V%P#L0RF0M0I"ME[SJQIG+1^C6=6!*_JB, Q4 M52(R%CMYI<"FK8DE+/5;_E!MKDCK,C"7O5N%W#(/'9#?KV5#U]ZD\%6?F@208;$,?61;37L!+]O$X\X^) M&%$I1[JM5E;,JD:KLK!ITO9\,X<<,RC%N2WME&GUZ@JGNE$KJ)N]/\M2"L[7 M%IS>^! 6%90D$9.)C'UK$K9A5->KI#:KZU4JZ+PI_^QOKH0]G9L37D(,DV * M^IIHIQA8K-2EG*WJR"LO9)\HS*F.D%CLU[6H>9K.R"OTBL>1J'.;M69U= M5I(?^Z9+S/0GJ\AX7M48N_G?EN-@!1C3/ID"JN,1GEN&-2*\0L1FA))^0(?L MW@]^\NQHBK5((>9N#_Q[7E02 VL,W ?\*E>ME-1,(1/[9;EQ5AL#*A6SL(!F M>PM+-H!'C?H65R@+/ MN:HHV,.=X\>A:!$1\,X98N4:^>;?8WF3,F,/0T;#&+8/\L>/79MX?H3=-_!" M>#58. >K.:'O)B\#2810P*\;L< 320&1O[WUH]:M$=MW71J,G\E!#EC?15BG MT#&Y.P6?#"@7-7IC5&6/RMZ%S:.@V1OC[]JRX)WQ^CU>E<=A08%;FU>.N!$\ MZ+B"/*C+Q-D(&%"8Y;A.5D=7N!QU!I$DE8-1TC8&#B2R)" 7>'YR1L(0UN:E M0G.)XW6[H8"&=^J$5@Q<5FQ\LK8I+:3)2H1D4[))HE>?JNW6WG5M][@W"J=F M9',*.:$>M:FH'SW'LBMR- 0.:U$E)YJ[:6$J,F_290'6K"KD-H#%>@]$;8@- M VO&;/1$A# ;#I"?'!P'^#.O?A;L6^'UL\S#NY.:WY"Z6 8[+F[F!;Q)R@HL M][A35;C $93T+ND=:!HHL@>ZITW.XL ? >D>A0[EQ"4TAJ3164;1YB1!/]D@ MZ!&UAZ 1IVI*)CG2 U C%TC7@MJY.I;0?T+Y<'7(4GAJ "?/TL(>7DIZ$,2] ML*O? ZZTX#;^3D>@50GU#L#A/;_@L*:%])C^[&&I/SS> 07)98PW^W)=_S[5 M '$?+DOEJ;APW$ L63L>W0;4YH<1/@S#VO;6:1XJ/XZ0%A^#QC&+U>;RT,I# M^\2AG2EJLIX8XZ8X>$@GQ8Z2G43RA-B)&3?-8%4''@B'=MPUXIA[5[ ,,4R6 M]<%,"KB+#0F9+XZ)DZ SX@,"IQ?SX\)31825F'6+P#-T0>&:7R< DI(8EY;K MA\+HX(P"M5A[?I^0M,'>X\,B53IY6N:W'T.5##N0F(/,.!7P% MCX %T^/18Q[K8QM(I.SM+5@Z[J,'A'L+A/WL@Q1D(HOX41\2[,DBA.HME[W3 M1V5\+J0PD.3]E#"8*BE1GJHIF10.JC[;)GE"-OC!]A;>V5Q<^:N1LPG_I="] MD),'C-\\V3\H?/E^"@'5_?I7.ASM'^6>)9H)\>UK>FWZ:?WMK6#2.DR$4DZH MFLNQII5<>Y/4EV>' *^_Q$=M+VUI,K:5I! MSB&I6U+W,]T]DYQR[LV:'[V')09CIYH^9=V,@ ;](7JM(Q?[EPNEBONJ@3*% M%V%[BYOARF2+/>QE1,.?V#K.C\'&3W@Y5\Q\%_\>-P7D+>*>HOFL?9XD>DGT M\P<.O#QY='P"FH]9?LK1'QVC[:WQ.8,SAY)S\)5U+NBY,UR>AN0WM:G5$CZ>=).;]%+EJ#[1H],P=S: 5OC\N*"B2QH&$=\>4'3IEA\YWUJ&SL6$= M.@'^2QX@.TYRM_(=.GV/NI.C6&3.@9274WI@Y_ &)-0Y1@,CS$X9.4 ZV)'[ M@MF.A?W.D6Q&<<]UP@$&+1D<>HU(ME&3^E%HH8N>CS DK3EYS<,*89=H@["\)T2/JQ9V>F?8V@/P+C-XS9209"' IM=$0?B.W? M>YD2VO.#@"<(A.APGFSL'P*P/N;WA@Q#0=A]_LYW>=]X"_YT(FR&S^&104QY M>)YTD%%,!#]EU!W2GR(.CE8-GZ[:XX(B8L#+.X ]T#,4GC[,9RXD^<&6#R?I MOSQ?F*43[H#=@SX)<@$@I/CA#I,]\;Q$X?96FHD.=X@1$&( 8'),J1M.F%?P M+\QR"QL3RL4T?3/]B=E+)_2J7HS<@+Z*%@$D [C$Z($;(R/W1LZ M(J\3OAXP=T1^H@!*^Y#C[:FHXM,1'D0&4QRE*$MG*<@3)T_P+/A MP=!"]U=(0/_"OWWAAL";_\2JCF[D6S\QRBFR[?G@R4^<[AKIG8Z7E7;@><5S MDQX=L!10I&UO'>.SN@):3!7TJPC M)ULX5]+$.'1_C*VAV>NO9&X!:M<)W^GYR!1QIHP#3!%GV2=C/FUFN=SC1%-7 M$6@<%GJR4I]0,H"IT1Y'(W ^#AM?P.>J<@V9HI?XL("H>!U&%MI&ENB[7-&?,01V.(15 M0DZK42!F[3Q-R5C5DCWM9("T>\I&/C!JH".4-6 %B)E)4\\[BC%2[SH4K(TN MJC[ VN&59">$[P*C_\CH050Q8/]WU.4.;#XQ K'),>-[6^IQ)NF@,>HWO&/')RVA%&.S\Z_,V& N_/NNC9K]WTW62E MI[ RSJX2+VKRO3?3]XZ>T/P;25];.LD)0$I?92VEW0$-4Z0AF=Y3/-+CQ+JC M[K_&>F<4N4*C'D>M@IA'O422'0>/8FIK-LO+AS, BK?0>T6!FN5[R#6X8$V1 MY413M(0@ [B8'7&+_#$0*5'S=IZJ$W,.A.-9+C#*.U;+>Z,>_W<=4W6!9_V1 MS%2V640==[[_9M4L*WDI_#79HI:%8WYR:MKTR+1L1''"_M.)T" 9U&R\,V<9 M5V!W@&%%<&'! 07!X_2J_"!IKB[BH"RPP8 $MK>HA<0ASN D@^DD Z+1"YGX M^^%!P"Q8,DAZS@1I $9X+6]]$4IUD("M7)+U^#E :I:+D]22P^Y8F"^71!5$ M >,_U"G7:/(*DP)&6"&E4_XX+M*S$L;\]FOD""X%V_2!,W#.<-)GIAC*)FES MK#@))^>#PG(@Y^9LC^!T_7+ 8&4@7J)[Y-3D+0&5=9XN1JN(N- M!CX?@)< EBCTSP[X?G;A=$N@G=@.Q10L\C\J66!&V;,\TJS7=PW3V#4;S=;4 M!+./2(R?L# Q6VN9E72UN=O4U%V]J6O3*Z59]V)%?"T\7)#5=M(PM'P;Y4.K MJ35-?AS@K4]C_#%J05PY[FQVMI;9W\"ECGIHX"0\8UTLZBA;<>:D=1YI [IE M.%\Q&>>'_D+?C05SX)9IA'/Z^-O@9EQBNLTPUQ3"AB/_/GMA0SRR_+ (.\]A M@;*]);)J=X$_F*, M%0>&!\)S;DZ%G%Q>G2JYRA@+1!H.1P1&C8PL71$,V( -F(?2; 7$_>0LP.VM M;# BD&F$&P$N&H^P$"R)XOM]Q@UG,-T%(Z7("%&^@TZ0V-+)EL,(*#VUGY.@ MZP #L*BU\%F)H&!P?2\K@AGX@,8:.7Z 8P7'@M>RPT5,W,!KT=-AC>G;@9M= MIP^_)3,9)Y-#IY J\.TB!23Y-WW,1<7TSGB8:DZ/ICERPVOLU<:,;POURP#4 MT43!N/'1.1Z(RQ3N(N322M!V*J02Q8PK3/^;_$020U\&A-]J0-C4EPP(J[J, M"*>]52;;KR3Q85P@N3T-".NI@,J"P_"]WY^^0_"+TZ&>*[ MZ_K^3R"P=+;Q> DJ5@$Q+7I(@"*)'/TJ"?*,_0#;6^?P[ZUH2W#-N- ]$DQ? M;;<-KGF%7 3G%\POE5 SMQ7MJ=] J,%=^.6D>0*RY]_"JN#NC'X M3ZK<*UE%@)(?IIR?"C#Y@TMCSQJDEZ=ELJA!H V6SF)&RQ<42@<]7B)G;.9;O.&(1>,P M:\^2FHAP,UH# >CZ6-3D8- M=2;X(4OQA98>'Y#M.N.BO/FO!HRFQ%[!I5+@ MMK<&_86;LSRNE^4DF21#V='W6O3@[)9WO)\"3OY^2[H_C;N>TL^-RV: M=YQ;A0ITXF/71V3R.$\3)VQRU2"GF( ,3$J;GH%I-5I9Y_#C] AK$'=Q"$+J MF1G6G\H>8KUN)C:?C6F+LK'&*F=%%WK8:_#'-4\\;LI1T2]#G!P5O -%B2OAVERO1I;]:YIECW7"\I=="15L M#(8.Y-B+;'8XS[V/2A"4>MT 0;FN;N\% &OH#:5>M&W_)@K*RRQ'+?6\[ZV* MCE[CMU=>53*5!2>EES@@7='UJHYD5/66TJA+KO/BD=_E3?I6ZHVJCD9JF$JK M7="*D(R,I\D-_2!R_CL9\15#'R+JW?*<41P)@C57+YCMIU9AMI^IZ&9E^:&F MF,TEIJY+"U-:F-6P,#>%8][XV#W:?V04E&!;:HV&TC8J.'E-;9M*NRD%\@O( M:TXGS;UNJHM;7-8:]N#&B*VJC('2;R/-$!Z&DS=G'E.-]PI3"2#I#),N* M6,#":)I !'V4(!<_JG7%T!>1BY_6+!@_:DIKH8#2IPWG..?HM)_ND(N%V!%. M+(P&OIWK^%%:^/)C$ZRW5Z.SA27E[ NG8,6D1W5_'B:D>E9 $JZ4KQ6FN09H M5(OD-ZR$MQ6&3E/TYB+1KF<8G'1H2(>&=&BLTZ'QA(I?&JO30(];:%)Z.;S. M4#1C$2>'Y'62UU4/0U*AR_G;1/E8RO\B^JL4AZYJ ,,S"X:#UN+0;9B*:2[A MT-TPB(D91DR$HP" M5349K.@S;.);#*5N%4B+$.IMZM+6+I2;Q0LCC@0/3@.GAJ@MD3#H3<]DD9_ M[FFA84> M]AJ\3_;>6T1G7PW\..?RI: ?R+9[8^YZU.V>W713[KD*H_(U?GOE53?1NW"2 M#%46#1%DX=NF\X(3', IAA7!A_&8R#)2!XG:TA35J&+X$'O^J)KT7C[?C,7B MXY_2.9KH,BDU_UYO-Q2SL:XFKT6A,S1L["(#TR_*4KV#FWV<,U9:DJK1JG)# M*;VM-'69[_PL)5T%;$0?DA%+XY&#$XI2::&7AJG46^MJO5D8.LQC5)=/?7@C MZ8)O*\_WQ52P,1B2@G1<._DZ[*Z0BJVH356IMRN8%HVPZ8;2:"[?1_W=D]-" M65X)M:4Q5^F,D*Q(:&+8+BQZ4'#$LB>F5J-+(AL)648G'M(P-:7=6E?WS6*0 MM12]^9+4EPUC2N/^YSS(#' N/2R,DF@ZDJ3>.UJ%7V\ZD> M<7_U??O><=V<\3KN?!R6ZGW3E(;14+2BI1=K,V !OI:I-(KF-FXB"SUE?1:( MKMKC\O I]VUOE>Q<:1F*452G7Y]SI=U4=&-C:C'?ENM .E>D&.)CABP=MJ-XG;%6BP>@*T)0EN5 ^TJ>>@E6RS"%C>+"9;'T'1,*E$, MHXJ>98"MWE*:YO(=W-\(0WMK_23*8&EO#4=2UTO2:L\[1\>=\\X-%DKPRHF; MRY/_]^WR_/3LNOO7OZAZ-'Y^;//9EZNW%B,$V]=1W:2&FD,QU59(?OZT8K]9-L;H1STTAO2SR M%+ [YL6E3:4VFTI[;<4IA8$SE>8R0U@WE[/EVUVO6@LK^A;;=:5=M$?2VDBL MU5"THFQV$_E5=^ 'T6[$@B&Q6:\\J:@J[79EQU:^ +BWZ_-\6R$*&<21_L[B MA0,Y@Z ,'X9AU(MGRZS%AV$8!O Z68?W*I4#TIJYWME.U2;AF(VI$/U MW9(?3]AW?: _[J5X!=6]<&1&J>M5Y7, 6]'4,536E75WRTIK OV2^?"4=B=+5*EVMKUM&5+); M5E5TLZF8KU:/OB1LK;:B%VTX(WFCY(W5P- FJH""$Y;,U< B;+241KV*X2:$ MS0"NNWQ+ \G5)%>3&E]YQ42R>&B!:.>FT,.)/QSZ'@DCW_I92G[%VIK0OBI4 MDKGP:A';=G! WB(VY8@Z-JR6VI,6'3F@@97GS#4:=:6N%G26KM&9:ZAH5\I M^[-$>,TBZGBY\<[EQ9Z,>AW^OZJ-H#1%;S05O:B'6;(Z;B\&?(KGPVHE9]%7 M^%%5FEI#T1;RPW\J@\A>#.$FLJXCRXJ'LE5/),2ZXGHTT+1)MXP^-*\3S9W*Y"/.^M M-6XK@^N]-1P=B+G1\ ^.9<<+R,$H!6(2AL>CW4F>X9A3H]Y?;6;]]-1V3)*O M[Y,+/V D^9S,FL=]G7;^"9L\X=>*<>N(!-AB]."R+W_+,?D>Z\,C]JA[3Q_" MOR%2OL$)[?P?[*"Q VP1K]_A^O#>7]K\?U-CZA.X3LZ^WYQ=XS1Y(F!(%C\ M4#)?M&-'@SVS9CBP'^HZM]Z7'>3NN1GT^#[(R=DY3A8_Z7S_^F6GOL/_OCHZ M/4W_GEC_^/+Z].R:?Y\L([[9!:#/CZZZ9WOIAV(B;!KAZ9#Q\?3Z! Q33\?5 M%YQKG^TC>\!ZY?%!Y_#ZXI3\[@1A1/X1TP#V2;2Z5B=GB?N67 4L#,DU$S4M M"9U=6I'?PTMUA8AA[9VEF#0"DXJ026D#$%[!_G&!Y/9C_ [N;XE%C_%S\E/G MT.]/7]E.+QNC-SOTJSGQR#K6=>9A3]=GW8NS4]+Y?E(3W2A_''<[IYVC:VQ/ MF<:0 ;VS0%*U%<"$0)SXJ("%S";PB>N ?,7/3[Q,^A?IWU[\/GX-K M%:C"E_WQAT=CVP%0]LEOQ/%(-/#C$+2[\!,1=##!H'./U\9O?2X13+#YJK.J M^R&S>OKS2A_V&ES0G,$$BZK0SSM%X?4!,< 7S>EWDFXD45X2LN)F6S1M MMMT, L9 LGO1("1G<-3L!16[=X X;1G$==D(&!"()K%@HZX<'%\?"A'UNM[P M5X;?+$( X]._P9Y,E%(H@/I< /4#?TC\K$*76I%SES:8D&E7&^8 ^LZB%4?S M"E4HX'SM5^MLN11D=4-I-62_P14=O.U MFIO+OBAEDWP7XWJ[/8K.*DSH8EXHR-_RPQ*GE"Z:E5=*OK.FZ$4;5$G^*GI9 MA"&A410XO3C"]A6H]8DP,AFR:.!C![([)C3%THBOJ9B2X;U;&NP,1]0)N"D" M$CXAO@I0G:88[NAL8ND"1\1'T&I5L['1;PP)67NFXMPZ$W/V<^17\Z5PDT,;DI/ M]F!D@B/V^\SBGZ@%S#'D17/2Z[+QK"P;VA8PBSEWJ+UQFBE-7IJ*9E;51-#J M2J/H<+E-9% =T+N\R ]2!E1>K9JN:/5%?&8EB3M#:2[4+'&>Q-M3HRC'EE49JV&*@55V%O]U6Z@L-197ED[*0J'H8DK(XS2Q9*,A?2N))4U,: MK^;X708RW514=?G>=N^>O&;DM G'KLQID_Z,1W9!'%@#BKJ7WT=^!%PH>E#( MR*6H]H,ZAJ&!T;#$B20?-4UIMHI:?6LT2C6EW2YJ,V\B7[JB$=J2 ;MUPBBH M0'C]HZ;4FT5[D:R/L(#L%PHW26?'-*4=IV&EO.\^<^USU8O_$F#)Q,MHKUH1 M['5RNZ:B-U;0P.?=$^&$9*U 9!WX24NOKAC5%'VA(?:2VSUV[?JP8SLDG\G' M*_K B>P3 >$ZI%$<8%X'$"!6;SNWZ7@YZX%'V0.P!LJC1P/HL:C?='WTV "E MLZ@?4#K:I*.M&AC:1(&;N=7BD$>T9GH]2G"I?6PT%&VA2H25<+HBD*GH4UMH M7H04NPNXV?J.1SU+NMGFN=DVA30RC4PX7\,P!K+@"8]6KI=_J:D>AM),8WH>2!R1[X]]@,+XLS9%^5&^4RFH92KU>UIJI1;Q2'3O(\,45GE.-Z M&?V5QM*:J@ZOLKH>7;.IJ V9J+M KQ$'L](\6Q@3Y<4'<'I]=:6DH2FMA5KZ MRPB!C!!4#T-2AD[$##XF08-/Y/-$6NXLEVX9,02UCH4)50PB$%77%7.93DN2 M$4I&6 U&N"EL[RRK;F>_+%X=3P(:,6(EE?+H,0&N6 :C QNB<'K96F*E#45; M*D%)\I>?O<"9J2ML7X?*M9C:&6K849 MO;'*H9:%'O8:$D0.M7P;B*OP4,O2=R%'6Q;UMCPA%$KPJZ@M55$7RGE?&4D6 M D_7%;4A6U47G@V6]M$!2HNH=^N@/T!T"X8M@+K5_3%#Y3"-#_ODCL&#+.KN MZ&"X'?!$=]:,$MBJA!7G!'T>TWG:_A2Y^MX&+MPN&YO M8;[""Q]F.VZ,C3A8&I#)W-*)-Q<=U#/=N;F9\+@^_V[^TX0?' >XX)N1/M^W MY_/-/%9OU'DIO;Z5\I=NH-=WXWT;4W*C#(5:JRL@UBJK4-<-I=602>LK]/)F MW4XB^BOUF6UO+>XU(]5PF^F*JJTW.%$4Q+;27J;<8G.YXF(>WSP=DY<0?]2Z-4ZE 69^#C>@R=[JSXG1D.T**ND_EWB2!46O&'G( M.=4J(^.+V"\-0VFTJANO4)N*9L@"I8IZX26F9!3WJ:9_(K; PPDA\>,H!%/? M=KS;\HQR0ZD7#7^N'4;L5R/;E[[46SD_HE5&[6^]9JYR\/&J@6LM,19A4ZBJ ML$KX1$SU+:J(0"8+-24MBX;-E_3PV%Z@8OAET>S5AJ5S\>[IL/ATV#Q? IN> M45ZL2[Z0>:WP'D$Y7T2J&L67L!A M$W[7D!?J8=J",X0S*MRO UZP]UST(>1)$?9\U^[V5MZWRU/-X-'P*\.?LT?[ MWJW/V^]D:6@*?W*/N0X\,X2;:)0,$O,#K*;S6-^)Q /%"G@[/#J$741L&.+, ME3[%XLH(.^I1,L0*[R&CR%WZL3L%@)C'&*4 P+/@ _KU<&)0C60<9"*%9GMV M 6-S3@I-GM/J'PIW&>=O;!(ASW+9Q?-@L)Z1>H!+FX_II6Z:P).T DEQP1?> MWAJ_"@ONB@'K@&\PZ$?XJ#$2086-W0C?5W3/F =_CY"F!'H=WPYK)-E8'"Z2 M*O2X0I/#Q=^B@_%N -Q]P"PQ\!,]_M*7!_\"%C^&.T(/8*9+<(G;81\Z'<_*Q?.WD2-8+86OL&L M_C@3M(N\@BS/B^\15K'%P*,P'HW$F".!=<_GF()U77B2QM2 MR-X:LK>&[*WQ=GIKM&5OC3)[:PA5M/< !.+;,7!K%"G7[!9E30K%Z^%E5HN, M[:W"/3)6;6@MR+;:6C72AHWVHGS+7&7:<'4?UMJP)A:J+O.9JY0)O%GYS)78 MQ0>QT F?"; *P%\?Y!,P@B+J18CN$VY!6P_)VB\NYE[\W,JV(T(%P@PUA9Q0 MC]J4*S_GZ$L@1T,6 )[?QCST35W[U5;=Q*;MSK%+F1:EFL[;>R'FA7D!: M;94-EE 9ZD4KQJI;@$S5WISXW5P[&XS&;G,6!/V(*.0H=FBL!@(5_,AP +U,6 MJKNVU%+?1\J"H58X90& 6V_?E:)ZZB*1W96D+!1VL!4$3 JG"F4UM+2*IPPT MM8J?2W65WN65 K8Q@R7>D4D@\23QM"X3L53 M-%8)W2KA6FT_R/&A^G;6^?KMYLN..:E?C+\>UQ3IZ[Y$VC")@^VKZ_=XTP]> M%"W]:%5>6_K1WH4?K=$P:Y6=P-+0]%K!#G!K%J.+F.NE^-&:TH_V=OUHFF%4 M7'W4U&;5/6FKY&K2D_;^[7J))XDGZ4F3GK2-\Z09;;VZ*9^&7E^S?5)8GJ\R MY+E2P%[2/'OC30!9#U7(C2SKH=8$F#0#*J"V23Q)/$DS0)H!;[:\JVFJ:_:H M%]'U37/-71<*J]2+N-5+T?67'U/_1K2)MS8=4&)*8FJMF*H K%7 T8$ M1H%U/,)I@H\Q$B.#""7]@ [9O1_\Y ,*:!BR,,0Y1 /_GOAQ(,;3N _X52^& M7QA>D2-^-K2A.AW[=LPP( MBP41=;S*+4G*7C M,$7=(WP!9GDG?CR],_X5C;G- MA(@^G+U]<_I;',/%Y=4-Q'#G7&E'C#T\/"3Y3"BK9>7(@DTR73"(XU;_K]NO M\$]M?03G.9F%XWYRG+Q/TC[9F:!$;A'ZO728#+HX@]P;A)P['$':8_TCYK4@ M34>#]Z.C$_C\"3YRZ] HN!4%=L&Z7!@QOW/P>_9'L T76BF4$A=P*117F> 2 MOK2D_X0KE25P+B5,/,P2+XOF'O.DL?IH\Y'-[K#@;]\ 4,J4'2DR617CR.>B M2<7CU,A$FSG+G6%N42(CI9BTT(@LZD#_'[>!H5IXB5T"9]Q. ZB5A/S$O30> MI!V<*?(E1*A[M$Z;Q* M*#I?+ ]*>_VC#B1'L80$:A:S9*[O&0FV._%:8GM( M_5YO0(ZMHZQC!R*%^K$#X<53:HVNDPW(PR TN%PR()TC5+NGL;16'_':F%' MVXIL>\@D\"&GG9"Y7VA07...5)#^5^K?B4LP$YD&+.KM Y9[H/-5P MW,S1W? ";S;I^LOH5VC,P\ "!TLBE(;!W4C7^LL3-B. M&OA?<5NZV%_%:9^RD)"Q"-0&\1UU!_9J(FU'O(C(LIWV)F*?:WY_B%=3\!R' M78/SXFRL[P>?BZ'/17J\5RXV]LM/8*+5S6O)=);D(82V#JH_Q*N)W:L\:T/^ M\AY17&1A#Y_41T_DY B*_QK.Z6SYGQ=WNUTO[X7&Z_!)U=*N^"HRX27I5 S MW5S1I1^P43ME$YQ!V,[>VJPTND3C!+UAJT&M#=P9G(TC>L3B=@5^ MEWR:T IL-3;L/YU\+V8$07F]8M=BG7 >?.W%X.7T+<#ETK3OSG%D*>VRLSE^ M;;2EP4.C)8BEIR<4[?F@/W>T#H[=^[DE#?"'KY.KG8_7\O5BCC]JI8M%S?-" M9Y5_(]O_YRK_J(C=XHI:RQ2!602"GKD)J7_?2WW)LV6:(WV?BM"_:<__T6=G M:Z%[Y"J'VAQT[)VR=2/K]BN+^=_J+)PS+K-*+O/>@!N-7<#UBNV/7#%['M?< MMC5KYYBM#W)STQWX^JI>./3S/U!+ P04 " "Z@%A/08FF+V@& !+1 M% ')M9"TR,#$Y,3 R-%]L86(N>&ULS9QM;]LV$,??%^AWN'EO-J"RHZ3H M&B-)$3C)$"QI@L;=A@U#(4N,34SF&:2=%6E8[_N[_\ M.X9Z<(X^K>8A/#"I.(KCGMO?ZP$3/@9<3(][2^5XRN>\!RKR1."%*-AQ;\U4 M[]/)VS='/S@.G%U>]@_R(^3S#."$'@1&X*[-]A_ M/S!1X+K#@X_#][_ [36<>RIB4L"8SUE^,"[6DD]G$?SD_QQKPQD*P<*0K>&" M"T_XW OA+BOZ'5P*OP^G80A?S#"EZU),/K"@GZJ&7/P[-']-3+7P]@V /I%" MQ?N.>^9TI&=C-9%A'^54%[MW,,B&])Y&K+:&/![$ ]S#P\-!?#0?K;@M5HN[ M@S^OK^[\&9M[COX ] ?FIVD4'ZIX_Q7Z\4FL4" 41IC_.5F88W8Y[KYSX/97 M*NB=F(3IV?$F++S26Q![&$H,64EB])9I[O"9">6.2*5Q*#5F=#SCVW-6E4_[V(XP+36"Q3%-H"W6(V(W M20!/&<"D:$QP>W7G0:Y;/ 7.IW,]@^L_T47H3:MR_&Q01P#;2T?+P2;(6H2( M6/VN#$:Z,:,M%)J'LVJU='/L2">37GBI5QBKW]BZWB2[-;C36;;("I8$-9]G MK8*T$VV: N(,LDQ.!?!F;YZKTOEL\$=XVFW@B5!%,!: M!*G)35* S@$F"1G$+91NI;ER_73+ATOAHUR@C&^JW$4ZZPB7>K9?CS"H><6V M0ZK3I44UFUAY2/-E1P5YVD7(1D*(,T*:$DQ.HC7)_^#+LD)YN3FZ5KK@(?N\ MG$^8K-ZC+0/W7X M/4]NJ;^$W4*13D'>90TK!#='O%28EG>="C9ST=+?JA5+*[S #UUCG :!MJ'2 M?ZZX8&Z]IK *=-H0999P1V#S1B@4I6V"5/]=M@$F$]P(JI5-:S8L#? "+^0- M,-*;-W*,C^)%^.>'OP;X+79LZ#^%D8'_7+(E[$T:0 DF$2WRU ;*@*_F@ASV M^)+A1MY*?.#"KWGE6Z3Q&K O,F9C_UDL60-8=5OJ@N3:3P.49:-MA5:LE/5# M#3_D37&+*O+"O_BB_LT@N\)K: B[*5L[;$22-8-%M:562#*!3D5Y@Z<]&V5M M4-D+R6M5QJ9D7AWL-\=T]5*5K7#91K5,T!:Y_ M2!Y%3(QP/E^*]/:-JLILP>".P"VW@B5!31 N$23B.,T FRD:L]QBX7F@ZU9/ M ?4=AMSG$1?3:[T>E]P+JQ)M&]D1SB4FL"BB"&\E,[W"-!SQ.SGFZPCRYOZ^^E*B3*$CF"N8PEV13>#>I4H$N4X#^3R0 M)((X4V/C[!RDOS9X,Z M5>.EH.-D'4(D3$ M9ZH,B71C-ELH- ]FU6HIY]#SE3_3GEF=;T':QW8\EUJ-8'$,Q9RZK4<]KV89 M:+X%V5[=UOFU8O%TSP;/YTQ.=0?]*O$QFNE%RL(3-;]V5B#1Z=/!/)[(/2>_P!0 M2P,$% @ NH!83^I@PJ? ! #BL !0 !R;60M,C Q.3$P,C1?<')E M+GAM;-6:76_B.!2&[T>:_^#)W.Q*DX1 I].BTA&B[0IM/Q PNZN]&9GD -8Z M-K)#@7^_QP%7!$(7NCNKN!>0.GZ/7Y_'<1R3JZ_+E)-G4)I)T?*BH.81$+%, MF)BTO+GVJ8X9\XC.J$@HEP):W@JT]_7Z_;NK#[Y/;NZZC\0GTRR;Z688+A:+ M(!DSH26?9QA2![%,0^+[MGYG^(W\MFZN2=H)MD/.Z\%Y [FE.@,ER)"EL"V6LY5B MDVE&?HI_SF.3&RD$< XKH8DV$3E M3/S5-!\CXY:\?T?P#U,I=%[:\DQ"-OE8CA0/I)J@W5HCM")O6[/<$RT:N22Z MO+P,\[/%^IJ5U<8&HO"/A_M!/(64^H@!L<4[3:&;)'M1;YO['*Y/VOJ:-74> MZ5[&>?*/Z!8Y6,/\Y]MJOBGRH[K?B(*E3KQKT^0ZJTIRZ,.8F.]O_>Y+FTP\ M@\ZD"A3H%$F8@96/@*B&0R&C2REDN@J-++R1\3P%D=GOMDAN1<:R55>,I4KS MSG@DSVMSJF#<\E2:^#:8^QX+ M"@)89B 22&P8X__']?EZC78S?F5HCG(,^37H@VU MCUCTO2-Q]FB/=*9HG!5SP9ME5J M!%3+J]<#G!4\,E-,*JR&)1Z9:[0D9\8\Y>8*,ZR&O.8/ M(=?&P9N8 7S'Z>189#NBZK+:,6HA-1R#M!YR'>R'HKR+\]?R5UB==GWMB:L+ M[8!A"^_,,7CV#C'$9![+K*BI+JJB3TOHW%%"/4#'>!M/;G#5>RJJ'7'UF>T8 MMO"^. ;/KKIBJ692Y1D>8**A(^3H"=1K3;5W5 6Y[M;0NG:0UI,MN@LE@8[9^HGT+NH-!JL[QH/$-U$;-2:CM M),%4Z\T7/F!#=!K0T@!5AUEJVH*,7 ;9P<,G-90+\2:,VW)'(&Y;M@A=>VPO M="B_RS^IGI+/S&Q OH7C7@Q'8.[YMD3=?,;?]*HG=4;YGVQV^O*U/((C-'=< M6Y:N/?*;&::M@)Y"KZBI+J^B3TOHLV.$S&\LO#>5XL3'B7U==4GM>[6T7-N@ M^1U=9B Z,DWG8K.:UL'S\1/E:A.HR?,VU9>G:7LQ.G[I: MST']>Z(E<9SA6N)]0_?,M4V9 <1S8S2JCX8LXT==KL$I'\NC;X(ZHNIQVC%I(KNVMV.%VNXRG5$S@E)=9RK7515;NUY)S#DY,2YH=&U02P$"% ,4 M " "Z@%A/ ^*H)VD# O# $ @ � XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d806534d8k.htm d806534dex991.htm rmd-20191024.xsd rmd-20191024_lab.xml rmd-20191024_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false XML 11 d806534d8k_htm.xml IDEA: XBRL DOCUMENT 0000943819 2019-10-24 2019-10-24 RESMED INC false 0000943819 8-K 2019-10-24 DE 001-15317 98-0152841 9001 Spectrum Center Blvd. San Diego CA 92123 (858) 836-5000 false false false false Common Stock, $0.004 par value RMD NYSE false XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d806534d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d806534d8k.htm" ] }, "labelLink": { "local": [ "rmd-20191024_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "rmd-20191024_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "rmd-20191024.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rmd", "nsuri": "http://investor.resmed.com/20191024", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d806534d8k.htm", "contextRef": "duration_2019-10-24_to_2019-10-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d806534d8k.htm", "contextRef": "duration_2019-10-24_to_2019-10-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20191024/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Document and Entity Information
Oct. 24, 2019
Cover [Abstract]  
Entity Registrant Name RESMED INC
Amendment Flag false
Entity Central Index Key 0000943819
Document Type 8-K
Document Period End Date Oct. 24, 2019
Entity Incorporation State Country Code DE
Entity File Number 001-15317
Entity Tax Identification Number 98-0152841
Entity Address, Address Line One 9001 Spectrum Center Blvd.
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92123
City Area Code (858)
Local Phone Number 836-5000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.004 par value
Trading Symbol RMD
Security Exchange Name NYSE
Entity Emerging Growth Company false